计算机辅助胸部X线联合尿液脂阿拉伯甘露聚糖检测增强住院HIV成人结核诊断(CASTLE研究):整群随机试验
在马拉维Zomba中心医院住院的HIV成人中,将入院日随机分为增强结核诊断(尿液SILVAMP-LAM与Determine-LAM抗原检测联合数字胸部X线计算机辅助诊断加常规诊疗)或单纯常规诊疗。增强组结核治疗启动率22.2% vs 常规组11.5%(风险比1.92,95%CI 1.20-3.08),56天死亡率、24小时内治疗启动及出院时未诊断结核无显著差异。
要点
- 增强结核诊断组结核治疗启动率高于常规组(22.2% vs 11.5%,风险比1.92,95%CI 1.20-3.08)。
- 56天死亡率两组无显著差异(26.1% vs 25.0%,风险比1.05,95%CI 0.72-1.53)。
- Determine-LAM与SILVAMP-LAM尿液检测一致性差,需进一步研究。
核心结论
- 尿液SILVAMP-LAM/Determine-LAM联合dCXR-CAD诊断较常规诊疗识别出更多住院HIV成人结核。
- 结核治疗增加主要因更多使用Determine-LAM而非SILVAMP-LAM或dCXR-CAD。
- Determine-LAM与SILVAMP-LAM尿液检测一致性差需进一步研究。
- HIV成人住院死亡率仍高得不可接受。
研究设计与样本
- 在马拉维Zomba中心医院开展的整群随机试验,纳入住院HIV成人。
- 入院日随机分配至增强结核诊断(尿液LAM抗原检测SILVAMP-LAM与Determine-LAM、数字胸部X线计算机辅助诊断dCXR-CAD加常规诊疗)或单纯常规诊疗。
- 2020年9月2日至2022年2月15日招募419人,排除4人后415人纳入改良意向性分析,来自207个随机分配入院日。
- 主要结局为住院期间启动结核治疗;次要结局为56天死亡率、24小时内结核诊断及出院时未诊断结核(通过一次入院痰培养确认)。
主要发现
- 入院时90.8%(377/415)正在接受抗逆转录病毒治疗,中位CD4细胞计数240 cells/mm3。
- 增强诊断组中位CAD4TBv6评分60(四分位距51-71),SILVAMP-LAM阳性4.4%(9/207),Determine-LAM阳性14.4%(29/201),3份样本两种尿液检测均阳性。
- 结核治疗启动:增强结核诊断组46/207(22.2%)vs 常规诊疗组24/208(11.5%),风险比1.92(95%CI 1.20-3.08)。
- 56天死亡率:增强结核诊断组54/207(26.1%)vs 常规诊疗组52/208(25.0%),风险比1.05(95%CI 0.72-1.53),无显著差异。
- 24小时内结核治疗启动:增强结核诊断组8/207(3.9%)vs 常规诊疗组5/208(2.4%),风险比1.61(95%CI 0.53-4.71),无显著差异。
临床怎么用
- 作者认为尿液SILVAMP-LAM/Determine-LAM联合dCXR-CAD诊断较常规诊疗可识别更多住院HIV成人结核。
- 作者指出结核治疗增加主要因更多使用Determine-LAM而非SILVAMP-LAM或dCXR-CAD。
- 作者认为Determine-LAM与SILVAMP-LAM尿液检测一致性差需进一步研究。
- 作者指出HIV成人住院死亡率仍高得不可接受。
局限性
- Determine-LAM与SILVAMP-LAM尿液检测一致性差需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with human immunodeficiency virus (PHIV) admitted to the hospital have high mortality, with tuberculosis (TB) being the major cause of death. Systematic use of new TB diagnostics could improve TB diagnosis and might improve outcomes. METHODS: We conducted a cluster randomized trial among adult PHIV admitted to Zomba Central Hospital, Malawi. Admission days were randomly assigned to: enhanced TB diagnostics using urine lipoarabinomannan (LAM) antigen tests (SILVAMP-LAM, Fujifilm, Japan and Determine-LAM, Alere/Abbot, USA), digital chest X-ray with computer-aided diagnosis (dCXR-CAD, CAD4TBv6, Delft, Netherlands), plus usual care ("enhanced TB diagnostics"); or usual care alone ("usual care"). The primary outcome was TB treatment initiation during admission. Secondary outcomes were 56-day mortality, TB diagnosis within 24 hours, and undiagnosed TB at discharge, ascertained by culture of one admission sputum sample. FINDINGS: Between 2 September 2020 and 15 February 2022, we recruited 419 people. Four were excluded postrecruitment, leaving 415 adults recruited during 207 randomly assigned admission days in modified intention-to-treat analysis. At admission, 90.8% (377/415) were taking antiretroviral therapy with a median CD4 cell count of 240 cells/mm3. In the enhanced diagnostic arm, median CAD4TBv6 score was 60 (interquartile range: 51-71), 4.4% (9/207) had SILVAMP-LAM-positive and 14.4% (29/201) had Determine-LAM-positive urine with 3 samples positive by both urine tests. TB treatment was initiated in 46/207 (22.2%) in the enhanced TB diagnostics arm and 24/208 (11.5%) in the usual care arm (risk ratio, 1.92; 95% confidence interval [CI]: 1.20-3.08). There was no difference in mortality by 56 days (enhanced TB diagnosis: 54/207, 26.1%; usual care: 52/208, 25.0%; hazard ratio. 1.05; 95% CI: .72-1.53); TB treatment initiation within 24 hours (enhanced TB diagnosis: 8/207, 3.9%; usual care: 5/208, 2.4%; risk ratio, 1.61; 95% CI: .53-4.71); or undiagnosed microbiological-confirmed TB at discharge (enhanced TB diagnosis, 0/207 [0.0%], usual care arm 2/208 [1.0%]; P = .50. INTERPRETATION: Urine SILVAMP-LAM/Determine-LAM plus dCXR-CAD diagnostics identified more hospitalized PHIV with TB than usual care. The increase in TB treatment appeared mainly because of greater use of Determine-LAM, rather than SILVAMP-LAM or dCXR-CAD. Poor concordance between Determine-LAM and SILVAMP-LAM urine tests requires further investigation. Inpatient mortality for adults with human immunodeficiency virus remains unacceptability high.
引用
- Burke RM, Nyirenda SK, Mtenga T, et al. Enhanced Tuberculosis Diagnosis With Computer-aided Chest X-ray and Urine Lipoarabinomannan in Adults With HIV Admitted to Hospital (CASTLE Study): A Cluster Randomized Trial. Clin Infect Dis. 2025. PMID: 38748183. doi:10.1093/cid/ciae273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。